基于结构的设计和优化甲氨基基转移酶2A (MAT2A) 抑制剂具有高选择性,大脑透性和体内有效性
Faridoon1, Jiyue Zheng1, Tao Zhang1
1Center for Drug Design and Development, Suzhou Genhouse Bio Co., Ltd., No. 1 Xinze Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China.
Journal of medicinal chemistry
|May 31, 2024
概括
准甲氨基基转移酶2A (MAT2A) 为MTAP被删除的癌症提供了一个新的合成致死性策略. 化合物39是一种新的MAT2A抑制剂,在临床前模型中显示出高强度和有效性.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 合成致死性是一种有前途的策略,用于准以前无法治疗的突变.
- 甲氨基基转移酶2A (MAT2A) 是一种经过验证的瘤除基因甲基氨酸酸化酶 (MTAP) 的瘤标.
- 开发MAT2A的选择性抑制剂对于精确的抗癌药物开发至关重要.
研究的目的:
- 发现和优化基于pyrazolo[3,4-c]quinolin-4-one支架的MAT2A新型抑制剂.
- 在MTAP删除的癌症模型中评估化合物的临床前疗效.
主要方法:
- 基于结构的药物设计被用来识别新的MAT2A抑制剂.
- 实验室试验用于确定酶抑制和细胞活性对MTAP删除的癌症细胞系.
- 在异种移植模型中进行了药理动力学研究和体内疗效评估.
主要成果:
- 发现了一系列针对MAT2A的新型pyrazolo[3,4-c]quinolin-4-one衍生物.
- 化合物39对MAT2A表现出高强度,对被MTAP删除的癌细胞具有显著的选择性.
- 化合物39表现出有利的药理动力学,包括高血暴露,口服生物可用性和体内显著的疗效.
- 观察到化合物39的脑透率很好.
结论:
- 化合物39是MTAP删除癌症的有希望的治疗候选者.
- 通过新型抑制剂 (如化合物39) 向MAT2A是一种可行的合成杀伤性方法.
- 对化合物39进行进一步的临床研究是有必要的,因为它在治疗特定类型的癌症方面具有潜力.
相关概念视频
01:28Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
01:19Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
00:49Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K